VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California. VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the research and development of compounds for the treatment cardiovascular and metabolic diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its principal product, VIA-2291, is in Phase II clinical trials in patients with acute coronary syndrome and patients with stenosis of the carotid artery. The company has agreements with Hoffmann-LaRoche Inc. and Hoffmann-LaRoche Ltd. to develop and commercialize two sets of compounds for the treatment of cardiovascular and metabolic disease.

Vion Pharmaceuticals was founded in 1992 and is based in New Haven, Connecticut. On December 17, 2009, Vion Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Vion Pharmaceuticals, Inc., a development-stage pharmaceutical company, develops and commercializes therapeutics for the treatment of cancer. It has two agents in clinical trials, Onrigin and Triapine. Onrigin, a novel alkylating agent that damages DNA to prevent cancer cells from reproducing, is in various clinical trials for the treatment of various indications, such as acute myeloid leukemia (AML), relapsed AML, de novo poor-risk, small cell lung cancer, brain tumors, myelodysplastic syndromes, chronic lymphocytic leukemia, hematologic malignancies, and solid tumors. Triapine is a small molecule in various clinical trials to prevent the replication of tumor cells by blocking a critical step in DNA synthesis. Vion company's other products and product candidates include MELASYN, a water-soluble, synthetic version of melanin for formulation of skin care products and cosmetics; and Nucleoside Analogs, known as elvucitabine, which is in Phase II clinical trials as an antiviral drug for the treatment of human immunodeficiency virus.

Accentia Biopharmaceuticals, Inc. (Accentia) is a biopharmaceutical company focused on the development and commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease and oncology. The Company operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products with an emphasis on the respiratory and oncology therapeutic areas. The products developed in this segment are SinuNase, BiovaxID and Revimmune. This segment also includes the Company’s consulting business, which provides a range of services relating to biopharmaceutical product development, and its biologics products business. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by its third-party development partners. In this segment, Accentia sells the Respi~TANN, SinuTest and Zinotic.

ReNeuron wants to renew damaged brain cells with stem cell therapy. Founded in 1997 by leading scientists at the London-based Institute of Psychiatry, the company is researching the feasibility of transplanting stem cells into patients with Parkinson's disease, Huntington's disease, type 1 diabetes, stroke, and other neurological disorders. ReNeuron also is studying the possible use of stem cells to treat brain tumors and in non-therapeutic areas with its ReNcell drug development platform. Investors include Merlin Ventures, a leading UK biotechnology investor.

Roche Holding (UK) is the holding company for Roche Products Limited and Roche Diagnostics Limited. The two UK subsidiaries develop and manufacture various products and equipment for the diagnosis and treatment of disease. Its pharmaceuticals include Copegus, a hepatitis C therapy; HIV inhibitor Fuzeon; and breast cancer therapy Herceptin. The firm's diagnostics arm makes a variety of consumer and professional tests, including Accu-Chek glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics.

OrthoLogic Corp., doing business as Capstone Therapeutics, focuses on the development and commercialization of therapeutic peptides and other molecules for patients with under-served conditions. The company's product includes Chrysalin, or TP508, a 23-amino acid synthetic peptide, which is under pre-clinical testing for vascular applications, such as acute myocardial infarction and chronic myocardial ischemia. It also offers AZX100, a synthetic 24-amino acid peptide to relax smooth muscle, which modulates blood pressure and the function of blood vessels, airways, sphincters, the gastrointestinal tract, and the genitourinary tract. AZX100 is also evaluated for medical and commercial applications, such as treatment of pulmonary disease, prevention of hypertrophic and keloid scarring, and intimal hyperplasia. The company was formerly known as IatroMed, Inc. and changed its name to OrthoLogic Corp. in July 1991. OrthoLogic Corp. was founded in 1987 and is based in Tempe, Arizona.

Centocor Ortho Biotech has ways of making your immune system behave itself. The Johnson & Johnson subsidiary makes blockbuster biotech drug Remicade, a monoclonal antibody used to treat a number of autoimmune conditions, or diseases in which the body's immune system attacks its own tissues. It is approved in the US and Europe for several indications, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis (a type of arthritis of the spine). The company also makes oncology drugs Doxil and Leustatin, and immunosuppressant Orthoclone for organ transplantation.

Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

Zeltia SA is a Spain-based holding company primarily engaged, through its subsidiaries, in the chemical and pharmaceutical sectors. Its main subsidiaries are: PharmaMar SA, biopharmaceutical company committed to advancing the treatment of cancer; Noscira SA, engaged in the research and development of innovative drugs for diseases of the nervous system; Genomica SAU, specializes in molecular diagnosis; Sylentis SAU, focused on the discovering and developing new therapeutic approaches based on gene silencing techniques; Zelnova SA, which produces and markets cleaning products for household and cetring sectors; and Xylazel SA, producer of paints, varnishes, wood and metal protectors for the industrial sector.

GE Healthcare Medical Diagnostics helps your doctor to see right through you. The division, formerly Amersham plc, is one of the world's top producers of contrast-imaging agents and nuclear medicine agents used to enhance image quality in X-ray, magnetic resonance imaging, and ultrasound procedures. General Electric formed the division when it acquired Amersham and placed under its GE Healthcare umbrella. The former Amersham bioscience operations, which makes purification systems that allow for the development of more effective drugs through protein analysis, DNA sequencing, and genetic variation, is part of the GE Healthcare Life Sciences division.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.